menu019.png

Management team

Pedro Esnaola

President

  • Pedro has developed his professional career in the area of management and marketing and communication in several multinational companies, such as Lintas Worldwide or Ruiz Nicoli Euro RSCG. He has been CEO of Publis NCM for 20 years.

  • He is now President of the Chamber of Commerce of Gipuzkoa and Honorary Consul of Slovenia, as well as investor and Board member of different start-ups.

  • He is also the President of the Basque Country Biotech Cluster.

  • Graduated in economics from the University of the Basque Country and holds a MBA from the University of Deusto.

Laureano Simon

CEO

  • Laureano Simón began his business career with the creation of Progenika Biopharma, S. A. in 2000. The Progenika Group companies are pioneers in the development, production and commercialization of molecular diagnostic systems and clinical therapy based on Genomics and Proteomics tools.

  • With extensive experience in the field of clinical diagnostics, he has established relationships with numerous pharmaceutical companies. Laureano Simón also serves as an advisor to various scientific committees of public institutions and private foundations. He has published numerous articles in high impact scientific journals and has received several awards in his professional career.

  • Laureano holds a PhD in Chemistry (Molecular Biology) from the Autonomous University of Madrid, a Master's degree in Biotechnology from the University of Navarra, a Master's degree in Science from the University of Wisconsin-Madison in the United States and a Bachelor's degree in Pharmacy from the University of Santiago de Compostela.

  • Laureano invests and promotes biotechnological projects, including Patia (focused on the prevention of diabetes) and Oncomatryx (treatment of solid tumors in cancer).

Manuel Sanz

CFO

  • Manuel has held several positions in the Purchase, Logistics, and Planning areas at large corporations such as Electrolux, as well as in biotech start-ups such as Oncomatryx

  • Held international project leadership positions in purchasing and logistics

  • Graduated from Universidad Santiago de Compostela and holds a Master in Business Administration from ESADE

Yosu Vara

Chemistry and Manufacturing Director

  • Yosu has been a founding partner of Quimatryx and Ikerchem.

  • Has 16 years of experience in the biotech and pharmaceutical industry, where he has been managing projects in the area of drug discovery. He has published more than 20 patents and publications in organic chemistry. He co-directed a doctoral thesis.

  • Yosu holds a Ph.D in Organic Chemistry from the University of the Basque Country

Eneko Aldaba

R&D Director

  • Eneko has been a founding partner of Quimatryx and Ikerchem.

  • Has 18 years of experience in the biotech and pharmaceutical industry, where he has been involved and managed in more than 10 project in the area of development of new anticancer drugs. He is author of more than 16 patents and publications.

  • Eneko holds a Ph.D in Organic Chemistry from the University of the Basque Country.

Ignacio García-Ribas

Chief Medical Officer

  • Ignacio Garcia-Ribas is a medical oncologist with 17 years of experience in early-stage oncology drug development. Most recently he was Chief Medical Officer of the Swedish company Cantargia where he created and implemented the initial development plan for Nadunolimab in both Europe and USA.

  • He previously worked at Takeda as global clinical lead on several Phase 1/2 programmes with a specific focus on immuno-oncology, and before that he was Senior Medical Director and a member of the Early Development Group of Sanofi’s Oncology Division where he was involved in the clinical development of small molecules and ADCs. Prior to that, he was part of the Early Development Unit at Eli Lilly, where he contributed to the development of several small molecules and antisense oligonucleotides.

  • Dr. Garcia Ribas received his PhD in Medicine from the Richard Dimbleby Cancer Research Department/ICRF Unit at St. Thomas’ Hospital in London, which focused on cancer gene therapy.

 

   QUIMATRYX

   Paseo Mikeletegi 69, 3┬¬ planta

   20009 San Sebasti├ín

   Tel: 946 08 70 37

   www.quimatryx.com